摘要 : PURPOSE: TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor-copositive metastatic breas... 展开
作者 | Kaufman B Mackey JR Clemens MR Bapsy PP Vaid A Wardley A Tjulandin S Jahn M Lehle M Feyereislova A Revil C Jones A |
---|---|
作者单位 | |
期刊名称 | 《Journal of clinical oncology :》 |
总页数 | 9 |
语种/中图分类号 | 英语 / R73 |
馆藏号 | N2007EPST0002224 |